| Name | Title | Contact Details |
|---|---|---|
Joanne Rioux |
Vice President of Sales and Marketing | Profile |
The Legal Marketing Association (LMA) is a not-for-profit organization established in 1985, dedicated to supporting professionals in legal marketing, business development, client service, and communications. With over 4,200 members from 49 U.S. states and 28 countries, LMA serves a diverse community that includes in-house marketers, consultants, lawyers, and marketing students. The organization emphasizes ethical standards, thought leadership, and professional advocacy. LMA provides a range of professional development resources, including educational programs, networking opportunities, and publications. Its Body of Knowledge (BoK) framework defines essential skills for legal marketers, while various events and webinars promote knowledge sharing and innovation. LMA fosters a collaborative environment where members can connect, share best practices, and advance their careers in the evolving landscape of legal marketing.
Coach & Equipment Mfg. Corp is a manufacturer of mid-sized buses serving the paratransit industry. With roots dating back to the 1870s, Coach & Equipment has a long history of manufacturing excellence. We pride ourselves in building safe and reliable buses that are carefully engineered and manufactured at our plant in Penn Yan, New York. In an industry that is becoming increasing consolidated, our company remains family-run and passionate about providing outstanding customer care.
We make pictures that sell your products.
For 25+ years, MIRACORP has served government and commercial clients. SMALL BUSINESS DESIGNATIONS -100% Woman-owned (WOSB) GSA Schedules: MAS - 47QSHA20D000Z NAICS CODE SERIES 541 - Professional, Scientific, Technical and Administrative Services 561 - Administrative and Facilities Support 611 - Educational Services
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.